These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 21177747)

  • 21. Updated 2013 College of American Pathologists/American Society of Clinical Oncology (CAP/ASCO) guideline recommendations for human epidermal growth factor receptor 2 (HER2) fluorescent in situ hybridization (FISH) testing increase HER2 positive and HER2 equivocal breast cancer cases; retrospective study of HER2 FISH results of 836 invasive breast cancers.
    Singh K; Tantravahi U; Lomme MM; Pasquariello T; Steinhoff M; Sung CJ
    Breast Cancer Res Treat; 2016 Jun; 157(3):405-11. PubMed ID: 27180259
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetic alterations and protein expression of HER2 and chromosome 17 polysomy in breast cancer.
    Zhu X; Lu Y; Lu H; Yang W; Tu X; Cai X; Zhou X
    Hum Pathol; 2011 Oct; 42(10):1499-504. PubMed ID: 21676436
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The HER2 gene copies per tumor cell either before or after correction for chromosome-17 correlated significantly with HER2 IHC results in epithelial ovarian cancer in a tissue microarray study.
    Tsai WC; Lee MY; Chen FL; Wang PH; Lin WL; Ruan A; Li YJ; Wang SC; Chiang H; Han CP
    Arch Gynecol Obstet; 2011 Sep; 284(3):721-9. PubMed ID: 21046136
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical role of HER2 gene amplification and chromosome 17: a study on 154 IHC-equivocal cases of invasive breast carcinoma patients.
    Afzal M; Amir M; Hassan MJ; Hussain MS; Aziz MN; Murad S; Murtaza I; Anees M; Sultan A
    Tumour Biol; 2016 Jul; 37(7):8665-72. PubMed ID: 26738861
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Co-amplification of the HER2 gene and chromosome 17 centromere: a potential diagnostic pitfall in HER2 testing in breast cancer.
    Varga Z; Tubbs RR; Wang Z; Sun Y; Noske A; Kradolfer D; Bosshard G; Jochum W; Moch H; Öhlschlegel C
    Breast Cancer Res Treat; 2012 Apr; 132(3):925-35. PubMed ID: 21698407
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Amplification of the HER2 gene in breast cancers testing 2+ weak positive by HercepTest immunohistochemistry: false-positive or false-negative immunohistochemistry?
    Barrett C; Magee H; O'Toole D; Daly S; Jeffers M
    J Clin Pathol; 2007 Jun; 60(6):690-3. PubMed ID: 16822876
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Observer prediction of HER2 amplification in HercepTest 2+ breast cancers as a potential audit instrument.
    Going JJ
    Histopathology; 2011 Aug; 59(2):333-5. PubMed ID: 21884213
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gastric HER2 Testing Study (GaTHER): an evaluation of gastric/gastroesophageal junction cancer testing accuracy in Australia.
    Fox SB; Kumarasinghe MP; Armes JE; Bilous M; Cummings MC; Farshid G; Fitzpatrick N; Francis GD; McCloud PI; Raymond W; Morey A
    Am J Surg Pathol; 2012 Apr; 36(4):577-82. PubMed ID: 22314190
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relative quantification of ERBB2 mRNA in invasive duct carcinoma of the breast: correlation with ERBB-2 protein expression and ERBB2 gene copy number.
    Mrhalová M; Kodet R; Kalinová M; Hilská I
    Pathol Res Pract; 2003; 199(7):453-61. PubMed ID: 14521261
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Amplification of Chromosome 17 Centromere (CEP17) in Breast Cancer Patients with a Result of HER2 2± by Immunohistochemistry.
    Davies V; Voutsadakis IA
    Cancer Invest; 2020 Feb; 38(2):94-101. PubMed ID: 31977265
    [No Abstract]   [Full Text] [Related]  

  • 31. Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours.
    Fleischmann A; Rotzer D; Seiler R; Studer UE; Thalmann GN
    Eur Urol; 2011 Aug; 60(2):350-7. PubMed ID: 21640482
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined detection of Her2/neu gene amplification and protein overexpression in effusions from patients with breast and ovarian cancer.
    Schlüter B; Gerhards R; Strumberg D; Voigtmann R
    J Cancer Res Clin Oncol; 2010 Sep; 136(9):1389-400. PubMed ID: 20217132
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Equivocal (HER2 IHC 2+) breast carcinomas: gene-protein assay testing reveals association between genetic heterogeneity, individual cell amplification status and potential treatment benefits.
    Pekar G; Kasselaki I; Pekar-Lukacs A; Dekany C; Hellberg D; Tot T
    Histopathology; 2019 Jan; 74(2):300-310. PubMed ID: 30113715
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessing the impact of polysomy-17 on HER2 status and the correlations of HER2 status with prognostic variables (ER, PR, p53, Ki-67) in epithelial ovarian cancer: a tissue microarray study using immunohistochemistry and fluorescent in situ hybridization.
    Lin CK; Lin WL; Chen FL; Lee MY; Kuo JF; Ruan A; Tyan YS; Chiang H; Chou MC; Han CP
    Int J Gynecol Pathol; 2011 Jul; 30(4):372-9. PubMed ID: 21623202
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinicopathological significance of HER2/neu genetic heterogeneity in HER2/neu non-amplified invasive breast carcinomas and its concurrent axillary metastasis.
    Shafi H; Astvatsaturyan K; Chung F; Mirocha J; Schmidt M; Bose S
    J Clin Pathol; 2013 Aug; 66(8):649-54. PubMed ID: 23539740
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fluorescence in situ hybridization of chromosome 17 polysomy in breast cancer using thin tissue sections causes the loss of CEP17 and HER2 signals.
    Jiang H; Bai X; Zhao T; Zhang C; Zhang X
    Oncol Rep; 2014 Nov; 32(5):1889-96. PubMed ID: 25119636
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of HER2 gene status in breast cancer by chromogenic in situ hybridization: comparison with immunohistochemistry.
    Kounelis S; Kapranos N; Malamos N; Kouri-Bairaktari E
    Anticancer Res; 2005; 25(2A):939-46. PubMed ID: 15868931
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Determination of HER2 amplification by in situ hybridization: when should chromosome 17 also be determined?
    Bartlett JM; Campbell FM; Mallon EA
    Am J Clin Pathol; 2008 Dec; 130(6):920-6. PubMed ID: 19019769
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic value of HER2 gene amplification detected by chromogenic in situ hybridization (CISH) in metastatic breast cancer.
    Todorović-Raković N; Jovanović D; Nesković-Konstantinović Z; Nikolić-Vukosavljević D
    Exp Mol Pathol; 2007 Jun; 82(3):262-8. PubMed ID: 17335803
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chromosome 17 polysomy: correlation with histological parameters and HER2NEU gene amplification.
    Orsaria M; Khelifa S; Buza N; Kamath A; Hui P
    J Clin Pathol; 2013 Dec; 66(12):1070-5. PubMed ID: 23908451
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.